

CYCLE 2021-01 - COVID 19 related requests

Note from Commission - <https://circabc.europa.eu/ui/group/5f872f83-e135-48a5-9fbf-829d9e32c8e5/library/40e3d725-60f9-4701-a40a-b177f852e061/details>

Sorting order:

First 'quotas', then 'suspensions'

>>>The duty suspension and quota requests on the following list are currently under discussion. The data available on this list may not represent the final state of the discussions within the relevant Commission Working group.

Please note that it cannot be guaranteed that the information available exactly reproduces an officially adopted text. Only European Union legislation published in the Official Journal of the European Union is deemed authentic<<<

CN code	TARIC	Reference Mail	Working Number	Description	Quota	New or amendment request	Measure status	Public Comments
2903 22 00		2418770/2020	1904	Trichlorethylene (CAS RN 79-01-6) with a purity by weight of 99,7 % or more	Q/10500000kilograms, 01.01-31.12	New	UNDER EXAMINATION	Round 2021-01 COM Machine Translation: Justification as a product with COVID-19 reference: This is due to the fact that trichloroethylene is used as a raw material for HFC-134a, which is also used for medical purposes; here: for propulsion of asthma inhalation equipment. It is particularly important for asthma patients to be well served and properly adjusted in the COVID-19 pandemic.

CN code	TARIC	Reference Mail	Working Number	Description	Suspensions	New or amendment request	Measure status	Public Comments
2925 19 95		2124802/2020	1901	N-Iodosuccinimide with a purity by weight of 98,5 % or more	S	New	UNDER EXAMINATION	Round 2021-01 Used for the production of a key intermediate for the production of Remdesivir, currently under Phase III clinical trials for the treatment of patients infect by SARS-CoV2 that could develop Covid-19.
2933 99 80		2124892/2020	1902	Pyrrole-2-carboxaldehyde with a purity by weight of 97 % or more	S	New	UNDER EXAMINATION	Round 2021-01 Used for the production of a key intermediate for the production of Remdesivir, currently under Phase III clinical trials for the treatment of patients infect by SARS-CoV2 that could develop Covid-19.
2914 29 00		2304183/2020	1903	4-(trans-4-Propylcyclohexyl)cyclohexanone (CAS RN 82832-73-3) with a purity by weight of 95 % or more	S	New	UNDER EXAMINATION	Round 2021-01 Used for liquid crystal production manufacture of blends used for LCD display manufacturing 1. LC displays are in many medical devices which are used both in the direct treatment of COVID-19 patients and in the research of therapies against COVID 19.

								<p>2. LC displays are installed in navigation devices that e.g. is used by emergency doctors and other mobile medical personnel.</p> <p>3. LC and OLED are installed in different devices, which are necessary for home office and imaging communication channels. Displays therefore have a direct influence on the feasibility of "social distancing".</p>
2903 99 80		2418944/2020	1905	2,2'-Dibromobiphenyl (CAS RN 13029-09-9) with a purity by weight of 95 % or more	S	New	UNDER EXAMINATION	<p>Round 2021-01 Intermediate for Organic light emitting diode (OLED) materials for displays. Due to their superior properties, OLED displays are contained in many medical devices, which are used both in the direct treatment of COVID-19 patients and in the research of therapies against COVID-19.</p>
2903 99 80		2419002/2020	1906	2-Bromo-9,9'-spirobi[9H-fluoren] (CAS RN 171408-76-7) with a purity by weight of 95 % or more	S	New	UNDER EXAMINATION	<p>Round 2021-01 Intermediate for Organic light emitting diode (OLED) materials for displays. Due to their superior properties, OLED displays are contained in many medical</p>

								devices, which are used both in the direct treatment of COVID-19 patients and in the research of therapies against COVID-19.
2921 49 00		2419061/2020	1907	2-(4-Biphenyl)amino-9,9-dimethylfluoren (CAS RN 897671-69-1) with a purity by weight of 95 % or more	S	New	UNDER EXAMINATION	Round 2021-01 Intermediate for Organic light emitting diode (OLED) materials for displays. Due to their superior properties, OLED displays are contained in many medical devices, which are used both in the direct treatment of COVID-19 patients and in the research of therapies against COVID-19.
2921 49 00		2419254/2020	1908	2-(2-Biphenyl)amino-9,9-dimethylfluoren (CAS RN 1198395-24-2) with a purity by weight of 95 % or more	S	New	UNDER EXAMINATION	Round 2021-01 Intermediate for Organic light emitting diode (OLED) materials for displays. Due to their superior properties, OLED displays are contained in many medical devices, which are used both in the direct treatment of COVID-19 patients and in the research of therapies against COVID-19.

(1) Suspension of duties is subject to end-use customs supervision in accordance with Article 254 of Regulation (EU) No 952/2013 of the European Parliament and of the Council of 9 October 2013 laying down the Union Customs Code (OJ L 269, 10.10.2013, p. 1)

